Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand.
actinium-225
bismuth-213
clinical application
internal radiotherapy
radionuclide production
targeted alpha therapy
Journal
Journal of labelled compounds & radiopharmaceuticals
ISSN: 1099-1344
Titre abrégé: J Labelled Comp Radiopharm
Pays: England
ID NLM: 7610510
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
11
06
2019
revised:
25
07
2019
accepted:
26
07
2019
pubmed:
2
8
2019
medline:
21
5
2020
entrez:
2
8
2019
Statut:
ppublish
Résumé
Targeted alpha therapy (TAT) is a promising approach for the treatment of cancer. The use of alpha emitters for cancer therapy has two distinct advantages over conventional therapies. The short range of alpha radiation in human tissue (less than 0.1 mm), corresponding to only a few cell diameters, allows selective killing of targeted cancer cells while sparing surrounding healthy tissue. At the same time, the high energy (several MeV) of alpha radiation and its associated high linear energy transfer leads to highly effective cell kill. Consequently, alpha radiation can destroy cells which otherwise exhibit resistance to treatment with beta or gamma irradiation or chemotherapeutic drugs, and can thus offer a therapeutic option for tumors resistant to conventional therapies. Recent results demonstrating the remarkable therapeutic efficacy of alpha emitters to treat various cancers have underlined the clinical potential of TAT. This paper describes the recent clinical experience with
Substances chimiques
Actinium-225
0
Bismuth-213
0
Radioisotopes
0
Actinium
NIK1K0956U
Bismuth
U015TT5I8H
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
794-802Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
Craver LF. Treatment of leukemia by radioactive phosphorus. Bull NY Acad Med. 1942;18:254. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1933770/
Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. JAMA. 1946;132(14):838. https://doi.org/10.1001/jama.1946.02870490016004
Magill J, Dreher R, Sóti Z. Chart of the Nuclides. 10th ed. Karlsruhe: Nucleonica GmbH; 2018 978-3-943868-51-7.
Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233. http://www.bloodjournal.org/content/100/4/1233
Rosenblat TL, McDevitt MR, Mulford DA, et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res. 2010;16(21):5303-5311. https://doi.org/10.1158/1078-0432.CCR-10-0382
Schmidt D, Neumann F, Antke C, et al. Phase I clinical study on alpha-therapy for non-Hodgkin lymphoma. In: 4th Alpha-immunotherapy symposium, Düsseldorf, Germany, 28-29 June 2004. http://itu.jrc.ec.europa.eu/index.php?id=205, p. 12 (abstract).
Allen BJ, Raja C, Rizvi S, et al. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther. 2005;4(12):1318-1324. https://doi.org/10.4161/cbt.4.12.2251
Raja C, Graham P, Abbas Rizvi SM, et al. Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther. 2007;6(6):846-852. https://doi.org/10.4161/cbt.6.6.4089
Allen BJ, Singla AA, Rizvi SM, et al. Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma. Immunotherapy. 2011;3(9):1041-1050. https://doi.org/10.2217/imt.11.97
Autenrieth ME, Seidl C, Bruchertseifer F, et al. Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study. Eur J Nucl Med Mol Imaging. 2018;45(8):1364-1371. https://doi.org/10.1007/s00259-018-4003-6
Autenrieth ME, Horn T, Kurtz F, et al. Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure [article in German]. Urologe. 2017;56(1):40-43. https://doi.org/10.1007/s00120-016-0273-4
Kneifel S, Cordier D, Good S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P. Clin Cancer Res. 2006;12(12):3843-3850. https://doi.org/10.1158/1078-0432.CCR-05-2820
Cordier D, Forrer F, Bruchertseifer F, et al. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging. 2010;37(7):1335-1344. https://doi.org/10.1007/s00259-010-1385-5
Krolicki L, Bruchertseifer F, Kunikowska J, et al. Targeted alpha therapy of glioblastoma multiforme: clinical experience with 213Bi- and 225Ac-Substance P. In: 10th International Symposium on Targeted Alpha Therapy. Kanazawa, Japan, 30 May - 1 June 2017, http://nucmed.w3.kanazawa-u.ac.jp/symposium/tat10/pic/photo/TAT-10_Programs/TAT-10 program (Low Res).pdf, p. 24 (abstract).
Kratochwil C, Giesel FL, Bruchertseifer F, et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41(11):2106-2119. https://doi.org/10.1007/s00259-014-2857-9
Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. An overview of targeted alpha therapy with 225actinium and 213bismuth. Curr Radiopharm. 2018;11(3):200-208. https://doi.org/10.2174/1874471011666180502104524
Krolicki L, Bruchertseifer F, Kunikowska J, et al. Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue. Eur J Nucl Med Mol Imaging. 2018;45(9):1636-1644. https://doi.org/10.1007/s00259-018-4015-2
Berger M, Jurcic J, Scheinberg D. Efficacy of 225Ac-labeled anti-CD33 antibody in acute myeloid leukemia (AML) correlates with peripheral blast count. In: 10th International Symposium on Targeted Alpha Therapy, Kanazawa, Japan, 30 May - 1 June 2017, http://nucmed.w3.kanazawa-u.ac.jp/symposium/tat10/pic/photo/TAT-10_Programs/TAT-10 program (Low Res).pdf, p. 22 (abstract).
Kratochwil C, Bruchertseifer F, Giesel F, Apostolidis C, Haberkorn U, Morgenstern A. Ac-225-DOTATOC - an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors. J Nucl Med. 2015;56:1232. http://jnm.snmjournals.org/content/56/supplement_3/1232
Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA targeted α-radiation therapy of patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941-1944. https://doi.org/10.2967/jnumed.116.178673
Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624-1631. https://doi.org/10.2967/jnumed.117.191395
Sathekge M, Bruchertseifer F, Knoesen O, et al. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46(1):129-138. https://doi.org/10.1007/s00259-018-4167-0
Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor-control. J Nucl Med. 2018;59(5):795-802. https://doi.org/10.2967/jnumed.117.203539
Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: Biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56(11):1697-1705. https://doi.org/10.2967/jnumed.115.161299
Allen BJ. A comparative evaluation of Ac225 vs Bi213 as therapeutic radioisotopes for targeted alpha therapy for cancer. Australas Phys Eng Sci Med. 2017;40(2):369-376. https://doi.org/10.1007/s13246-017-0534-6
Boll RA, Malkemus D, Mirzadeh S. Production of actinium-225 for alpha particle mediated radioimmunotherapy. Appl Rad Isotop. 2005;62(5):667-679. https://doi.org/10.1016/j.apradiso.2004.12.003
Samsonov MD, Nerozin NA, Podsoblyaev DA, et al. Isolation of alpha-emitting radionuclides for nuclear medicine in JSC ‘SSC RF - IPPE’. In: 10th International Symposium on Targeted Alpha Therapy, Kanazawa, Japan, 30 May - 1 June 2017, http://nucmed.w3.kanazawa-u.ac.jp/symposium/tat10/pic/photo/TAT-10_Programs/TAT-10 program (Low Res).pdf, p. 97 (abstract).
Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem. 2005;77(19):6288-6291. https://doi.org/10.1021/ac0580114
Zielinska B, Apostolidis C, Bruchertseifer F, Morgenstern A. An improved method for the production of Ac-225/Bi-213 from Th-229 for targeted alpha therapy. Solvent Extr Ion Exch. 2007;25(3):339-349. https://doi.org/10.1080/07366290701285108
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374-1403. https://doi.org/10.1016/j.ejca.2012.12.027
Apostolidis C, Molinet R, McGinley J, Abbas K, Möllenbeck J, Morgenstern A. Cyclotron production of Ac-225 for targeted alpha therapy. Appl Radiat Isot. 2005;62(3):383-387. https://doi.org/10.1016/j.apradiso.2004.06.013
Morgenstern A, Abbas K, Bruchertseifer F, Apostolidis C. Production of alpha emitters for targeted alpha therapy. Curr Radiopharm. 2008;1(3):135-143. https://doi.org/10.2174/1874471010801030135
Higashi T, Nagatsu K. National Institutes for Quantum and Radiological Sciences and Technology, Chiba, Japan, private communication.
Štursa J, Lebeda O. Cyclotron production of 225Ac. In: IAEA Workshop on the Supply of 225Ac, Vienna, Austria, 9/10 October 2018, http://www-naweb.iaea.org/napc/iachem/working_materials/Report_Workshop on Supply of Ac-225_IAEA_JRC_October2018.pdf, p. 30 (abstract).
Pozzi OR. Argentine project for 225Ac production. In: IAEA Workshop on the Supply of 225Ac, Vienna, Austria, 9/10 October 2018, http://www-naweb.iaea.org/napc/iachem/working_materials/Report_Workshop on Supply of Ac-225_IAEA_JRC_October2018.pdf, p. 31 (abstract).
Elema D. Development of 225Ac production from 226Ra. In: IAEA Workshop on the Supply of 225Ac, Vienna, Austria, 9/10 October 2018, http://www-naweb.iaea.org/napc/iachem/working_materials/Report_Workshop on Supply of Ac-225_IAEA_JRC_October2018.pdf, p. 32 (abstract).
Lee KC. 225Ac production at KIRAMS. In: IAEA Workshop on the Supply of 225Ac, Vienna, Austria, 9/10 October 2018 (unpublished).
Oh SY, Lee KC, Lim I, Jung H, Lim SM. Development of actinium-225 production method using liquid target. In: 11th International Symposium on Targeted-Alpha-Therapy, Ottawa, Canada, 1-4 April 2019. J. Med. Imag. Radiat. Sci. 50 (2019) S9, doi:10.1016/j.jmir.2019.03.027 (abstract).
Beyer GJ, Bergmann R, Schomäcker K, et al. Comparison of the biodistribution of 225Ac and radio-lanthanides as citrate complexes. Isotopenpraxis Isot Environ Health Stud. 1990;26(3):111-114. https://doi.org/10.1080/10256019008624245
dos Santos Augusto R, Buehler L, Lawson Z, et al. CERN-MEDICIS (Medical Isotopes Collected from ISOLDE): A new facility. Appl Sci. 2014;4(2):265-281. https://doi.org/10.3390/app4020265
Abergel R, An D, Lakes A, Rees J, Gauny S. Actinium biokinetics and dosimetry: What is the impact of Ac-227 in accelerator-produced Ac-225? In: 11th International Symposium on Targeted-Alpha-Therapy, Ottawa, Canada, 1-4 April 2019. J. Med. Imag. Radiat. Sci. 50 (2019) S23, doi:10.1016/j.jmir.2019.03.073 (abstract).
Dockx K, Cocolios TE, Stora T. ISOL technique for the production of 225Ac at CERN-MEDICIS. In: 11th International Symposium on Targeted-Alpha-Therapy, Ottawa, Canada, 1-4 April 2019. J. Med. Imag. Radiat. Sci. 50 (2019) S23, doi:10.1016/j.jmir.2019.03.072 (abstract).
Weidner JW, Mashnik SG, John KD, et al. Proton-induced cross sections relevant to production of 225Ac and 223Ra in natural thorium targets below 200 MeV. Appl Radiat Isot. 2012;70(11):2602-2607. https://doi.org/10.1016/j.apradiso.2012.07.006
Engle JW, Mashnik SG, Weidner JW, et al. Cross sections from proton irradiation of thorium at 800 MeV. Phys Rev C. 2013;88(1):014604. https://doi.org/10.1103/PhysRevC.88.014604
John K. US DOE tri-lab research and production effort to provide accelerator-produced 225Ac for radiotherapy: 2019 update. In: 11th International Symposium on Targeted-Alpha-Therapy, Ottawa, Canada, 1-4 April 2019. J. Med. Imag. Radiat. Sci. 50 (2019) S1, doi:10.1016/j.jmir.2019.03.004 (abstract).
Robertson A, Hoehr C, Lobbezoo A, et al. Ac-225 production using TRIUMF's 500 MeV cyclotron. In: 11th International Symposium on Targeted-Alpha-Therapy, Ottawa, Canada, 1-4 April 2019. J. Med. Imag. Radiat. Sci. 50 (2019) S18, doi:10.1016/j.jmir.2019.03.057 (abstract).
Harvey J. NorthStar program for production of Ac225. In: 11th International Symposium on Targeted-Alpha-Therapy, Ottawa, Canada, 1-4 April 2019. J. Med. Imag. Radiat. Sci. 50 (2019) S14, doi:10.1016/j.jmir.2019.03.046 (abstract).
Copping R, Mirzadeh S, Stracener D, et al. Radium targets for the reactor production of alpha-emitting medical radioisotopes. In: 11th International Symposium on Targeted-Alpha-Therapy, Ottawa, Canada, 1-4 April 2019. J. Med. Imag. Radiat. Sci. 50 (2019) S15, doi:10.1016/j.jmir.2019.03.049 (abstract).
Boll RA, Garland M, Mirzadeh S. Reactor production of thorium-229. In: International Conference on Nuclear Data for Science and Technology, Santa Fe, NM, USA, 26 September - 1 October 2004, AIP Conf. Proc. 769 (2005) 1674, doi:10.1063/1.1945330.
Maslov OD, Sabel'nikov AV, Dmitriev SN. Preparation of 225Ac by 226Ra(γ,n) photonuclear reaction on an electron accelerator, MT-25 microtron. Radiochemistry (Moscow). 2006;48(2):195-197. https://doi.org/10.1134/S1066362206020184
Schaffer P. 225Ac from photonuclear reactions at ARIEL. In: IAEA Workshop on the Supply of 225Ac, Vienna, Austria, 9/10 October 2018, http://www-naweb.iaea.org/napc/iachem/working_materials/Report_Workshop on Supply of Ac-225_IAEA_JRC_October2018.pdf, p. 22 (abstract).
Chemerisov S. Photonuclear capabilities at Argonne. In: IAEA Workshop on the Supply of 225Ac, Vienna, Austria, 9/10 October 2018, http://www-naweb.iaea.org/napc/iachem/working_materials/Report_Workshop on Supply of Ac-225_IAEA_JRC_October2018.pdf, p. 23 (abstract).
Grimm T, Grimm A, Peters W, Zamiara M. High-purity actinium-225 production from radium-226 using a superconducting electron linac. In: 11th International Symposium on Targeted-Alpha-Therapy, Ottawa, Canada, 1-4 April 2019. J. Med. Imag. Radiat. Sci. 50 (2019) S12/S13, doi:10.1016/j.jmir.2019.03.040 (abstract).